keyword
MENU ▼
Read by QxMD icon Read
search

SLE therapy

keyword
https://www.readbyqxmd.com/read/27916006/budget-impact-analysis-of-belimumab-in-treating-systemic-lupus-erythematosus
#1
Francesca Pierotti, Iaria Palla, Lara Pippo, Valentina Lorenzoni, Giuseppe Turchetti
OBJECTIVES: The study evaluates the costs of systemic lupus erythematosus (SLE) and the budget impact due to the introduction of belimumab in the Italian setting. METHODS: Adaptation to the Italian setting of a budget impact model with a time horizon of 4 years (year 0 without belimumab, years 1-3 with belimumab) to compare treatment, administration, and clinical monitoring costs of standard therapy and of the alternative scenario in which belimumab is administered in addition to the standard therapy to the subgroup of patients selected according to the label approved by the European Medicines Agency...
December 5, 2016: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/27902995/systemic-lupus-erythematosus-a-review-of-the-clinical-approach-to-diagnosis-and-update-on-current-targeted-therapies
#2
Joanne Szczygiel Cunha, Katarzyna Gilek-Seibert
Systemic lupus erythematosus (SLE) is a chronic, complicated and challenging disease to diagnose and treat. The etiology of SLE is unknown, but certain risk factors have been identified that lead to immune system dysfunction with antibody formation and immune complex deposition. This immune system dysregulation causes organ injury, contributing to the variable manifestations and relapsing-remitting course of the disease. Criteria were created to aide in the diagnosis, focusing on clinical manifestations and antibody profiles specific to SLE...
December 1, 2016: Rhode Island Medical Journal
https://www.readbyqxmd.com/read/27900357/datasets-of-yy1-expression-in-rheumatoid-arthritis-patients
#3
Jinpiao Lin, Yujue He, Junmin Chen, Zhiyong Zeng, Bin Yang, Qishui Ou
The data presented in this article are related to the research article entitled "A critical role of transcription factor YY1 in rheumatoid arthritis by regulation of interleukin-6" (J. Lin, Y. He, J. Chen, Z. Zeng, B. Yang, Q. Ou, 2016) [1]. The article describes YY1 overexpression is specific for RA, but not for SLE, SS, DM or MCTD. In early RA, YY1 expression is also increased. In asymptomatic subjects with RF or ACPA positive who have high risk for developing RA, the YY1 expression is not increased obviously...
December 2016: Data in Brief
https://www.readbyqxmd.com/read/27889859/chronic-high-dose-glucocorticoid-therapy-triggers-the-development-of-chronic-organ-damage-and-worsens-disease-outcome-in-systemic-lupus-erythematosus
#4
Tünde Tarr, Gábor Papp, Nikolett Nagy, Edina Cserép, Margit Zeher
Long-term survival of patients with systemic lupus erythematosus (SLE) improved worldwide; thus, prevention of cumulative organ damage became a major goal in disease management. The aim of our study was to investigate the chronic organ damages and their influence on disease outcome in SLE. We evaluated clinical conditions, laboratory findings and medications of 357 consecutive SLE patients and assessed their impact on Systemic Lupus Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) and disease outcome...
November 26, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27887663/effects-of-royal-jelly-supplementation-on-regulatory-t-cells-in-children-with-sle
#5
Asmaa M Zahran, Khalid I Elsayh, Khaled Saad, Esraa M A Eloseily, Naglaa S Osman, Mohamd A Alblihed, Gamal Badr, Mohamed H Mahmoud
BACKGROUND AND OBJECTIVE: To our knowledge, no previous studies have focused on the immunomodulatory effects of fresh royal jelly (RJ) administration on systemic lupus erythematosus (SLE) in humans. Our aim was to study the effect of fresh RJ administration on the disease course in children with SLE with some immunological markers (CD4(+) and CD8(+) regulatory T cells and T lymphocytes apoptosis). METHODS: This was an open-label study in which 20 SLE children received 2 g of freshly prepared RJ daily, for 12 weeks...
2016: Food & Nutrition Research
https://www.readbyqxmd.com/read/27884822/a-framework-for-remission-in-sle-consensus-findings-from-a-large-international-task-force-on-definitions-of-remission-in-sle-doris
#6
Ronald van Vollenhoven, Alexandre Voskuyl, George Bertsias, Cynthia Aranow, Martin Aringer, Laurent Arnaud, Anca Askanase, Petra Balážová, Eloisa Bonfa, Hendrika Bootsma, Dimitrios Boumpas, Ian Bruce, Ricard Cervera, Ann Clarke, Cindy Coney, Nathalie Costedoat-Chalumeau, László Czirják, Ronald Derksen, Andrea Doria, Thomas Dörner, Rebecca Fischer-Betz, Ruth Fritsch-Stork, Caroline Gordon, Winfried Graninger, Noémi Györi, Frédéric Houssiau, David Isenberg, Soren Jacobsen, David Jayne, Annegret Kuhn, Veronique Le Guern, Kirsten Lerstrøm, Roger Levy, Francinne Machado-Ribeiro, Xavier Mariette, Jamil Missaykeh, Eric Morand, Marta Mosca, Murat Inanc, Sandra Navarra, Irmgard Neumann, Marzena Olesinska, Michelle Petri, Anisur Rahman, Ole Petter Rekvig, Jozef Rovensky, Yehuda Shoenfeld, Josef Smolen, Angela Tincani, Murray Urowitz, Bernadette van Leeuw, Carlos Vasconcelos, Anne Voss, Victoria P Werth, Helena Zakharova, Asad Zoma, Matthias Schneider, Michael Ward
OBJECTIVES: Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. METHODS: An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting...
November 24, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27881354/-analysis-of-immune-suppression-in-patients-with-systemic-lupus-erythematosus-complicated-by-herpes-zoster-virus-infection
#7
Hui Ouyang, Xue-Chang He, Yi Zhou, Zhao-Xia Li
OBJECTIVE: To explore the changes in cellular immune function and the safety of physical therapy in patients with systemic lupus erythematosus (SLE) complicated by herpes zoster (HZ) virus infection. Methods A retrospective analysis was conducted among 10 SLE pateints with HZ virus infection, with 30 SLE patients without HZ infection as the control group. The results of routine laboratory tests and T lymphocyte subset counts (before and during infection and after cure of infection) were compared between the two groups...
November 20, 2016: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/27872476/new-insights-into-the-immunopathogenesis-of-systemic-lupus-erythematosus
#8
REVIEW
George C Tsokos, Mindy S Lo, Patricia Costa Reis, Kathleen E Sullivan
The aetiology of systemic lupus erythematosus (SLE) is multifactorial, and includes contributions from the environment, stochastic factors, and genetic susceptibility. Great gains have been made in understanding SLE through the use of genetic variant identification, mouse models, gene expression studies, and epigenetic analyses. Collectively, these studies support the concept that defective clearance of immune complexes and biological waste (such as apoptotic cells), neutrophil extracellular traps, nucleic acid sensing, lymphocyte signalling, and interferon production pathways are all central to loss of tolerance and tissue damage...
November 22, 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/27860434/interferon-targeted-therapy-for-sle-are-the-trials-on-target
#9
EDITORIAL
Elena M Massarotti, Heather G Allore, Karen Costenbader
No abstract text is available yet for this article.
November 11, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27848056/an-evaluation-of-health-related-quality-of-life-in-patients-with-systemic-lupus-erythematosus-using-promis-and-neuro-qol
#10
Jin-Shei Lai, Jennifer L Beaumont, Sally E Jensen, Karen Kaiser, David L Van Brunt, Amy H Kao, Shih-Yin Chen
Systemic lupus erythematosus (SLE) is a multi-organ chronic autoimmune disease that can negatively affect patients' health-related quality of life (HRQOL). This study evaluated HRQOL of SLE patients using questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) and Quality of Life in Neurological Disorders (Neuro-QoL). Individuals with SLE completed an online survey consisting of the PROMIS-29 health profile, PROMIS Psychosocial Illness Impact-Negative, and Neuro-QoL Applied Cognition...
November 15, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27843658/giant-condyloma-acuminata-in-indonesian-females-with-sle-under-immunosuppressant-and-steroid-therapy
#11
Andhika Rachman, Nabila Hasan
Introduction. Immunosuppressant and steroid therapy in systemic lupus erythematosus (SLE) increases the risk of human papillomavirus (HPV) infections, one of which is giant condyloma acuminata (GCA). To our knowledge, there is no report evaluating the correlation between immunosuppressive and steroid therapy in patients with SLE and the prevalence of GCA. Case Report. A 42-year-old female was diagnosed with SLE a year ago and has been treated with steroids and immunosuppressive drugs. In the last few months she presented GCA involving the genital area recurring almost every two months...
2016: Case Reports in Immunology
https://www.readbyqxmd.com/read/27833441/lupus-nephritis-in-children-10-years-experience
#12
Hanna Szymanik-Grzelak, Elżbieta Kuźma-Mroczkowska, Jadwiga Małdyk, Małgorzata Pańczyk-Tomaszewska
Systemic lupus erythematosus (SLE) in children is usually more severe than it is in adults and there is a higher incidence of renal involvement. We described 18 children (16 girls, 2 boys) with lupus nephritis (LN), whose average age was 14.4 ±1.81 years. Disease activity was assessed according to SLEDAI (SLE Disease Activity Index). Renal biopsy was classified according to the INS/RPS (International Society of Nephrology/Renal Pathology Society). The patients were treated with steroids (100%) and pulses of cyclophosphamide (88...
2016: Central-European Journal of Immunology
https://www.readbyqxmd.com/read/27821390/update-on-lupus-nephritis
#13
Salem Almaani, Alexa Meara, Brad H Rovin
SLE is a chronic inflammatory disease that affects the kidneys in about 50% of patients. Lupus nephritis is a major risk factor for overall morbidity and mortality in SLE, and despite potent anti-inflammatory and immunosuppressive therapies still ends in CKD or ESRD for too many patients. This review highlights recent updates in our understanding of disease epidemiology, genetics, pathogenesis, and treatment in an effort to establish a framework for lupus nephritis management that is patient-specific and oriented toward maintaining long-term kidney function in patients with lupus...
November 7, 2016: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/27819860/glucose-hypermetabolism-in-contralateral-basal-ganglia-demonstrated-by-serial-fdg-pet-ct-scans-in-a-patient-with-sle-chorea
#14
Na Niu, Ruixue Cui
We reported a 24-year-old woman who developed a movement disorder of mouth and limbs during systemic lupus erythematosus. Brain MRI did not find any abnormalities. Increased FDG uptake in basal ganglia was found using FDG PET/CT brain scan. The symptoms remitted after therapy and the activities of the original hypermetabolic regions were down to normal in the follow-up FDG PET/CT scan. This case implies that the pathophysiology of chorea in systemic lupus erythematosus is different from that of chorea in other diseases, such as Huntington disease and chorea-acanthocytosis, in which hypometabolic basal ganglia was found...
January 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27816459/microrna-21-microrna-181a-and-microrna-196a-as-potential-biomarkers-in-adult-egyptian-patients-with-systemic-lupus-erythematosus
#15
Tarek K Motawi, Dahlia A Mohsen, Shohda A El-Maraghy, Mona A Kortam
Dysregulation of miRNAs has been described in systemic lupus erythematosis (SLE), however the clinical relevance of using miRNAs as biomarkers for SLE or predictors of disease progression is poorly investigated. This study investigated the expression signature of plasma miR-21, miR-181a and miR-196a among seventy SLE patients with different systemic lupus erythematosis disease activity index (SLEDAI) scores and thirty healthy controls using quantitative real-time PCR. Plasma IL-10 level was also measured in patients and control groups...
November 2, 2016: Chemico-biological Interactions
https://www.readbyqxmd.com/read/27814627/oxidative-dna-and-mitochondrial-dna-change-in-patients-with-sle
#16
Hui-Ting Lee, Tsai-Hung Wu, Chen-Sung Lin, Chyou-Shen Lee, Siao-Cian Pan, Deh-Ming Chang, Yau-Huei Wei, Chang-Youh Tsai
We evaluated plasma IL-10, IFN-alpha, IL-23, IFN-gamma, IP-10, MCP-1, 8-OHdG, leukocyte mtDNA, serum anti-dsDNA antibodies and disease activity index (SLEDAI) in SLE patients. 93 patients (35 nephritis, 4 under dialysis, 5 under rituximab) and 50 healthy controls were recruited. Compared with healthy controls, SLE patients had higher IL-10, IFN-alpha, IL-23, IFN-gamma, IP-10 and MCP-1 (p<0.05). High IFN-alpha (p=0.031) and IP-10 (p=0.026) correlated with high SLEDAI; high IFN-alpha (p<0.001), IL-23 (p=0...
January 1, 2017: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/27812954/activation-of-the-mechanistic-target-of-rapamycin-in-sle-explosion-of-evidence-in-the-last-five-years
#17
REVIEW
Zachary Oaks, Thomas Winans, Nick Huang, Katalin Banki, Andras Perl
The mechanistic target of rapamycin (mTOR) is a central regulator in cell growth, activation, proliferation, and survival. Activation of the mTOR pathway underlies the pathogenesis of systemic lupus erythematosus (SLE). While mTOR activation and its therapeutic reversal were originally discovered in T cells, recent investigations have also uncovered roles in other cell subsets including B cells, macrophages, and "non-immune" organs such as the liver and the kidney. Activation of mTOR complex 1 (mTORC1) precedes the onset of SLE and associated co-morbidities, such as anti-phospholipid syndrome (APS), and may act as an early marker of disease pathogenesis...
December 2016: Current Rheumatology Reports
https://www.readbyqxmd.com/read/27812953/monogenic-lupus
#18
REVIEW
Mindy S Lo
PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease known for its clinical heterogeneity. Over time, new insights into the complex genetic origin of SLE have started to explain some of this clinical variability. These findings, reviewed here, have also yielded important understanding in the immune mechanisms behind SLE pathogenesis. RECENT FINDINGS: Several new monogenic disorders with lupus-like phenotype have been described...
December 2016: Current Rheumatology Reports
https://www.readbyqxmd.com/read/27812716/effects-of-statin-therapy-in-patients-with-systemic-lupus-erythematosus
#19
Rosa T Artola, Christos G Mihos, Orlando Santana
OBJECTIVES: Systemic lupus erythematosus (SLE) is associated with a significant risk of cardiovascular mortality. The use of statins for lipid modulation and the prevention of cardiovascular disease in this population also may impart pleiotropic anti-inflammatory and immunomodulatory effects. Our aim was to identify studies that compared the use of statins and placebo or no statin therapy in patients with SLE. METHODS: A meta-analysis was conducted on the follow-up measures of serum lipid levels, inflammatory markers, and disease activity, which was measured using the SLE Disease Activity Index (SLEDAI) score...
November 2016: Southern Medical Journal
https://www.readbyqxmd.com/read/27804088/first-real-world-insights-into-belimumab-use-and-outcomes-in-routine-clinical-care-of-systemic-lupus-erythematosus-in-germany-results-from-the-observe-germany-study
#20
Andreas Schwarting, Johann O Schroeder, Tobias Alexander, Marc Schmalzing, Christoph Fiehn, Christof Specker, Alessandra Perna, Constanze Cholmakow-Bodechtel, Volker B Koscielny, Heike Carnarius
OBSErve Germany was the first observational study of belimumab as add-on treatment for systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively collecting data from 102 SLE patients, 6 months before and after belimumab initiation. Most patients had moderate or severe SLE and several SLE manifestations. After 6 months of belimumab treatment, 78% of patients showed an improvement in overall disease activity of at least 20% in their physician's judgment and for 42% of patients the improvement was at least 50%...
December 2016: Rheumatology and Therapy
keyword
keyword
57199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"